Protagenic Therapeutics (MBP0) Stock Price & Analysis

0 Followers

MBP0 Stock Chart & Stats

€1.59€0.00(0.00%)

At close: Nov 10 5:30 PM GMT+1

Day’s Range: EUR 1.59 - EUR 1.59
52-Week Range: EUR 1.59 - EUR 1.83
Previous Close: EUR 1.59
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 799.77K
Enterprise Value: EUR 1.69T
Total Cash (Recent Filing): EUR 76.91K
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): 0.2
Beta: -0.63
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial Progress

Advancing clinical trials for PT00114 indicates progress in drug development, potentially leading to new revenue streams upon successful commercialization.

Innovative Therapeutic Approach

A unique therapeutic mechanism can create a competitive advantage in treating CNS disorders, enhancing market position and long-term growth prospects.

Intellectual Property Strength

Securing patents strengthens the company's intellectual property portfolio, protecting innovations and supporting long-term competitive positioning.

Bears Say

Financial Instability

Persistent financial losses and lack of revenue highlight challenges in achieving financial stability, increasing reliance on external funding.

Negative Cash Flow

Negative cash flow from operations indicates unsustainable financial practices, potentially limiting the company's ability to fund R&D and growth.

Deteriorating Equity

Decreasing equity reflects weakening financial health, which could hinder the company's ability to invest in future growth opportunities.

Protagenic Therapeutics News

Protagenic Therapeutics Enters $250,000 Promissory Note Agreement

An announcement from Protagenic Therapeutics ( ($PTIX) ) is now available. On November 4, 2026, Protagenic Therapeutics issued a $250,000 promissory note to Patness LLC, bearing 1% simple annual interest.

4d ago8K PTIX

Protagenic Therapeutics Advances PT00114 Toward U.S. IND

Protagenic Therapeutics ( ($PTIX) ) has issued an announcement. On August 20, 2026, Protagenic Therapeutics announced that the U.S. Food and Drug Administration had provided written feedback on its Type

2M ago8K PTIX

Protagenic receives FDA pre-IND feedback supporting IND for PT00114

Protagenic Therapeutics (PTIX) announced that it has received written responses from the U.S. Food and Drug Administration, FDA, to its Type B pre-Investigational New Drug, pre-IND, meeting request for PT00114,

2M agoPTIX MBP0

Protagenic Therapeutics Delays Quarterly SEC Filing

Protagenic Therapeutics ( ($PTIX) ) has released a notification of late filing. Protagenic Therapeutics, Inc. has filed a Form 12b-25, formally notifying investors that it will delay its Form 10-Q

2M agoPTIX MBP0

Protagenic Therapeutics Delays Annual 10-K Filing

Protagenic Therapeutics ( ($PTIX) ) has released a notification of late filing. Protagenic Therapeutics, Inc. has filed a Form 12b-25 with the SEC, announcing a delay in its Annual Report

4M agoPTIX MBP0

Protagenic Therapeutics announces publication of PT00114 preclinical data

Protagenic Therapeutics (PTIX) announced the publication of new preclinical data for its lead candidate, PT00114, in the peer-reviewed journal Behavioural Pharmacology. In a well-established rodent model of chronic unpredictable stress,

4M agoPTIX MBP0

Protagenic announces two engagements to support advancement of PT00114

Protagenic Therapeutics (PTIX) announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regulatory affairs veteran Dr.

5M agoPTIX MBP0

Protagenic Therapeutics appoints Nichols Jr. as President

Protagenic Therapeutics (PTIX) announced the appointment of Bill Nichols Jr. as President. At Protagenic, Nichols will drive integrated clinical development, corporate strategy, and enterprise planning as the Company prepares to

6M agoPTIX MBP0

Protagenic Therapeutics Announces Termination of Chief Financial Officer

Protagenic Therapeutics ( ($PTIX) ) has shared an announcement. On March 31, 2026, Protagenic Therapeutics, Inc. disclosed that its Board of Directors had decided to terminate the employment of Chief

7M ago8K PTIX

Protagenic Therapeutics completes Phytanix separation

Protagenic Therapeutics (PTIX) announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic’s capital structure, materially reducing liabilities and sharpens the

7M agoPTIX MBP0

Protagenic Therapeutics upgrades from OTC Pink to OTCQB Venture Market

Protagenic Therapeutics (PTIX) announced that its common stock has been upgraded from OTC Pink to the OTCQB and has commenced trading on OTCQB under the symbol “PTIX.” Published first on

8M agoPTIX MBP0

Protagenic Therapeutics Appoints William Nichols as President

Protagenic Therapeutics ( ($PTIX) ) has provided an announcement. On February 3, 2026, Protagenic Therapeutics, Inc. appointed William (Bill) Nichols, Jr., 51, as President, bringing in a leader with senior

8M ago8K PTIX

Protagenic Therapeutics Unwinds Phytanix Deal and Settles Litigation

Protagenic Therapeutics ( ($PTIX) ) has shared an announcement. On February 17, 2026, Protagenic Therapeutics, Inc. entered into a settlement agreement with Alterola Biotech Inc., EMC2 Capital LLC and the

8M ago8K PTIX

Protagenic Therapeutics announces delay in quarterly filing

Protagenic Therapeutics ( ($PTIX) ) has released a notification of late filing. Protagenic Therapeutics, Inc. has filed a Form 12b-25, notifying investors of a delay in its Form 10-Q (Quarter

8M agoPTIX MBP0

MBP0 FAQ

What was Protagenic Therapeutics’s price range in the past 12 months?

Protagenic Therapeutics lowest stock price was €1.59 and its highest was €1.83 in the past 12 months.

What is Protagenic Therapeutics’s market cap?

Protagenic Therapeutics’s market cap is €799.77K.

When is Protagenic Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Protagenic Therapeutics’s earnings last quarter?

Protagenic Therapeutics released its earnings results on Apr 01, 2024. The company reported -€4.752 earnings per share for the quarter.

Is Protagenic Therapeutics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Protagenic Therapeutics pay dividends?

Protagenic Therapeutics does not currently pay dividends.

What is Protagenic Therapeutics’s EPS estimate?

Protagenic Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Protagenic Therapeutics have?

Protagenic Therapeutics has 1,810,208 shares outstanding.

What happened to Protagenic Therapeutics’s price movement after its last earnings report?

Protagenic Therapeutics reported an EPS of -€4.752 in its last earnings report. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of Protagenic Therapeutics?

Currently, no hedge funds are holding shares in DE:MBP0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description